Jonathan Synett

Centauri Therapeutics Ltd. engages in manufacturing processing drugs in pharmaceutical preparations for life threatening diseases. The firm focuses on on the discovery and development of novel molecules targeting life threatening diseases. The company was founded by Mike Westby and Stuart Lawson and is headquartered in Sandwich, the United Kingdom.

NCL Technology Ventures Ltd. (NCL Technology Ventures) is an venture capital firm founded in 2010 by Jerry Biggs. The firm is headquartered in London, United Kingdom.

Viramal Ltd. operates as a biotechnology company and develops drugs for male and female sexual and hormone problems. The company was founded by Oliver Bates and Finn Larsen in 2013 and is headquartered in London, the United Kingdom.

Alert Technology Ltd. engages in the manufacture of electronic measuring and esting equipment. The company was founded on August 29, 2005 and is headquartered in Devon, the United Kingdom.

Avvinity Therapeutics Ltd. develops novel immuno-therapeutics. The British company was founded in 2016 by Mike Westby, Jonathan David Moore. The CEO is Nick Staples.

Northern Trust Global Investments Ltd. (NTGIL) is an investment management firm headquartered in London, UK. The firm was founded in 2000 and is a subsidiary of Northern Trust Management Services Ltd., ultimately held by Northern Trust Corp. (NASDAQ: NTRS) in the US. NTGIL provides passive and active investment advisory services for cash, fixed income and passive investment advisory services for equity portfolios and funds to institutional clients.

Ampersand Health Ltd. engages in the development of digital therapeutics for inflammatory conditions. It offers My IBD Care and My Arthritis. The company was founded by Nader Alaghband, Gareth Cecil Parkes and Bu' Hayee on September 24, 2018 and is headquartered in London, the United Kingdom.

Azadyne Ltd. is an Irish preclinical biotech company that has identified a new target within the body and a previously undrugged pathway to treat autoimmune diseases. Azadyne is based in Dublin2, IE. The company is able to selectively control natural regulatory pathways to modify specific pathogenic immune populations. The company's groundbreaking work in RNA modification has been supported by investment syndicates led by NCL. The company was founded in 2019 by Jason Rutt, Vincent Kelly, Stephen Connon, and Mike Southern to commercialize the pioneering work on the QTRT or TGT pathway carried out in Profs Kelly, Connon & Southerns labs at Trinity College Dublin.